Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciaf107 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von A Lianne Messchendorp und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Everolimus, Kidney Transplantation, Mycophenolic Acid, Immunosuppressive Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organization for Health Research and Development, Dutch Kidney Foundation.
Abstract (Originalsprache)
Background
Vaccine immunogenicity is reduced in kidney transplant recipients (KTRs), especially in those using mycophenolate mofetil (MMF). Whether replacement of MMF by everolimus improves vaccine immunogenicity is unknown.
Methods
KTRs were randomized 1:1 to continue MMF or switch to everolimus. Participants received one coronavirus disease 2019 (COVID-19) booster vaccination and two herpes zoster (HZ) vaccinations at 6, 10 and 14 weeks postrandomization. Primary outcome was the neutralizing antibody response 28 days after COVID-19 vaccination. Secondary outcomes included antibody and T-cell responses 28 days after COVID-19 and HZ vaccination, and safety.
Results
In 110 KTRs, COVID-19 vaccination resulted in comparable Omicron XBB.1.5 neutralizing antibody titers in the everolimus versus MMF group (308 [74.4–1314] vs 327 [115–897]; P = .83), whereas severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Spike-specific T-cell responses were slightly lower with everolimus (118 [32.1–243] vs 228 [113–381] spot-forming cells [SFCs]/106 peripheral blood mononuclear cells [PBMCs]; P = .02). HZ vaccination led to higher varicella zoster virus (VZV) glycoprotein E (gE)–specific immunoglobulin G titers with everolimus (2192 [888–4523] vs 1101 [440–2078] 50% endpoint titer; P = .004), while VZV gE-specific T-cell responses were similar (85.0 [27.5–155] vs 115 [50.0–258] SFCs/106 PBMCs; P = .24). Besides known side effects, everolimus led to more bacterial infections (27.3% vs 11.1%; P = .03).
Conclusions
Six weeks’ replacement of MMF by everolimus in KTRs does not improve COVID-19 booster vaccine immunogenicity, whereas 10 weeks’ replacement enhances humoral HZ vaccine immunogenicity. While replacing MMF by everolimus may improve vaccine responses, its timing and potential risks require careful consideration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Division of Nephrology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
- Cardiovascular Research Institute Maastricht, School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
- Division of Nephrology, Department of Medicine, Leiden University Medical Center and Leiden Transplant Center, Leiden, The Netherlands.
ORCID-Profile: A Lianne Messchendorp, Luca M Zaeck, Pim Bouwmans, Dennis A J van den Broek, Sophie C Frölke, S Reshwan K Malahe, Katharina S Schmitz, Frederique E Visscher, Luuk B Hilbrands, Hanna Källmark, Marcia M L Kho, Aiko P J de Vries, Arjan D van Zuilen, Rory D de Vries, Jan-Stephan F Sanders
Förderung
- Netherlands Organization for Health Research and Development
- Dutch Kidney Foundation
Zitieren
APA
Messchendorp, A. L., Zaeck, L. M., Bouwmans, P., van den Broek, D. A. J., Frölke, S. C., Geers, D., Imhof, C., Malahe, S. R. K., Schmitz, K. S., Reinders, J., Visscher, F. E., Baan, C. C., Bemelman, F. J., Gansevoort, R. T., GeurtsvanKessel, C. H., Hemmelder, M. H., Hilbrands, L. B., Källmark, H., Kapetanovic, M. C., …, & RECOVAC Collaborators (2026). Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf107
Vancouver
Messchendorp AL, Zaeck LM, Bouwmans P, van den Broek DAJ, Frölke SC, Geers D, et al. Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf107
BibTeX
@article{Messchendorp2026,
author = {Messchendorp, A Lianne and Zaeck, Luca M and Bouwmans, Pim and van den Broek, Dennis A J and Frölke, Sophie C and Geers, Daryl and Imhof, Céline and Malahe, S Reshwan K and Schmitz, Katharina S and Reinders, Julian and Visscher, Frederique E and Baan, Carla C and Bemelman, Frederike J and Gansevoort, Ron T and GeurtsvanKessel, Corine H and Hemmelder, Marc H and Hilbrands, Luuk B and Källmark, Hanna and Kapetanovic, Meliha C and Kho, Marcia M L and de Vries, Aiko P J and van Zuilen, Arjan D and Reinders, Marlies E and van Baarle, Debbie and de Vries, Rory D and Sanders, Jan-Stephan F and RECOVAC Collaborators, RECOVAC Collaborators},
title = {Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciaf107}
}
EUVIMED